DPP4 and type 2 diabetes mellitus: Meanwhile, in a multidose exploratory clinical study of T2DM patients (CTR20182505) the average inhibition rate of DPP-4 reached 80%, and the glycosylated hemoglobin was significantly reduced after six doses of oral administration, suggesting that HSK7653 has a significant effect on T2DM patients.